rs113298164

Variant summary

Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BP4_StrongBS2

The NM_000236.3(LIPC):​c.1214C>T​(p.Thr405Met) variant causes a missense change. The variant allele was found at a frequency of 0.00255 in 1,614,152 control chromosomes in the GnomAD database, including 19 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. T405T) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0028 ( 2 hom., cov: 32)
Exomes 𝑓: 0.0025 ( 17 hom. )

Consequence

LIPC
NM_000236.3 missense

Scores

3
7
8

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:3U:6B:3

Conservation

PhyloP100: 7.18

Publications

36 publications found
Variant links:
Genes affected
LIPC (HGNC:6619): (lipase C, hepatic type) Enables phospholipase A1 activity and triglyceride lipase activity. Involved in several processes, including lipid homeostasis; plasma lipoprotein particle remodeling; and triglyceride catabolic process. Located in extracellular space. Implicated in several diseases, including Alzheimer's disease; coronary artery disease; familial combined hyperlipidemia; peripheral vascular disease; and type 2 diabetes mellitus. Biomarker of hyperinsulinism; obesity; and type 1 diabetes mellitus. [provided by Alliance of Genome Resources, Apr 2022]
LIPC Gene-Disease associations (from GenCC):
  • hyperlipidemia due to hepatic triglyceride lipase deficiency
    Inheritance: AR, Unknown Classification: STRONG, LIMITED Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -8 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.015030295).
BS2
High Homozygotes in GnomAd4 at 2 AR,Unknown gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LIPCNM_000236.3 linkc.1214C>T p.Thr405Met missense_variant Exon 8 of 9 ENST00000299022.10 NP_000227.2 P11150A6H8L5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LIPCENST00000299022.10 linkc.1214C>T p.Thr405Met missense_variant Exon 8 of 9 1 NM_000236.3 ENSP00000299022.5 P11150

Frequencies

GnomAD3 genomes
AF:
0.00284
AC:
432
AN:
152174
Hom.:
2
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000386
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000852
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.0146
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00360
Gnomad OTH
AF:
0.000956
GnomAD2 exomes
AF:
0.00293
AC:
737
AN:
251448
AF XY:
0.00274
show subpopulations
Gnomad AFR exome
AF:
0.000554
Gnomad AMR exome
AF:
0.000665
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000163
Gnomad FIN exome
AF:
0.0157
Gnomad NFE exome
AF:
0.00307
Gnomad OTH exome
AF:
0.00212
GnomAD4 exome
AF:
0.00252
AC:
3682
AN:
1461860
Hom.:
17
Cov.:
32
AF XY:
0.00247
AC XY:
1794
AN XY:
727228
show subpopulations
African (AFR)
AF:
0.000329
AC:
11
AN:
33480
American (AMR)
AF:
0.000648
AC:
29
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.0000504
AC:
2
AN:
39700
South Asian (SAS)
AF:
0.0000580
AC:
5
AN:
86258
European-Finnish (FIN)
AF:
0.0163
AC:
868
AN:
53412
Middle Eastern (MID)
AF:
0.000520
AC:
3
AN:
5768
European-Non Finnish (NFE)
AF:
0.00236
AC:
2626
AN:
1111986
Other (OTH)
AF:
0.00228
AC:
138
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.473
Heterozygous variant carriers
0
215
430
644
859
1074
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
86
172
258
344
430
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00284
AC:
432
AN:
152292
Hom.:
2
Cov.:
32
AF XY:
0.00312
AC XY:
232
AN XY:
74472
show subpopulations
African (AFR)
AF:
0.000385
AC:
16
AN:
41558
American (AMR)
AF:
0.000851
AC:
13
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5192
South Asian (SAS)
AF:
0.000207
AC:
1
AN:
4824
European-Finnish (FIN)
AF:
0.0146
AC:
155
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00360
AC:
245
AN:
68026
Other (OTH)
AF:
0.000946
AC:
2
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
22
44
65
87
109
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00263
Hom.:
4
Bravo
AF:
0.00148
TwinsUK
AF:
0.00108
AC:
4
ALSPAC
AF:
0.00156
AC:
6
ESP6500AA
AF:
0.000456
AC:
2
ESP6500EA
AF:
0.00186
AC:
16
ExAC
AF:
0.00276
AC:
335
EpiCase
AF:
0.00240
EpiControl
AF:
0.00225

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:6Benign:3
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:3
Nov 09, 2020
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 32041611, 31589614, 31980526, 30333156, 28870971, 1671786, 24082139, 24497850, 20981092, 8732782, 1883393, 23685560, 8123642) -

-
Clinical Genetics, Academic Medical Center
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 24, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

LIPC: BS1 -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Hyperlipidemia due to hepatic triglyceride lipase deficiency Pathogenic:2Uncertain:1
Apr 27, 2017
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -

Jan 06, 2020
Reproductive Health Research and Development, BGI Genomics
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:curation

NM_000236.2:c.1214C>T in the LIPC gene has an allele frequency of 0.015 in European(Finnish) subpopulation in the gnomAD database.Functional studies demonstrate that p.Thr405Met has reduced enzymatic activity (PMID: 1883393). It was detected in multiple individuals with autosomal recessive Hepatic lipase deficiency, compound heterozygous with c.1214C>T (p.Thr405Met) (PMID: 1883393).The patient's phenotype is highly specific for LIPC gene (PMID: 1671786). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP criteria applied: PS3; PM3; PP4. -

Aug 01, 2003
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Type 2 diabetes mellitus Pathogenic:1
May 04, 2022
Mendelics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Uncertain:1
Jun 24, 2020
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant classified as Uncertain Significance - Favor Pathogenic. The p.Thr405Met variant in LIPC (also reported as p.Thr383Met in the literature) has been identified in the compound heterozygous state in at least 2 individuals with hepatic lipase deficiency and segregated with disease in 5 affected relatives from 2 families (Hegele 1991 PMID: 1883393, Hegele 1991 PMID: 1671786, Ruel 2003 PMID: 12777476 ). This variant has also been identified in the heterozygous state in 3 individuals with biochemical features consistent with hepatic lipase deficiency (Knudsen 1996 PMID: 8732782, Motazacker 2013 PMID: 23685560, Geller 2018 PMID: 30333156). Additionally, this variant has been reported in ClinVar (Variation ID # 14451) and has been identified in 1.5% (388/25112) of Finnish chromosomes, including 3 homozygotes, and 0.3% (460/129166) of European chromosomes, including 2 homozygotes, by gnomAD (http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that this variant impacts protein function (Knudsen 1996 PMID: 8732782, Durstenfeld 1994 PMID: 8123642); however, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain as it is unclear what clinical effect of the biochemical change in lipid levels has on people with hepatic lipase deficiency, particularly on how they affect the risk of atherosclerosis in some individuals and not in others and whether that risk is greater than individuals in the general population (Brunzell 2011 PMID: 21986251, Kobayashi 2015 PMID: 25995285). ACMG/AMP Criteria applied:PP1_Strong, PM3, PS3_Supporting. -

Type 2 diabetes mellitus;C3151466:Hyperlipidemia due to hepatic triglyceride lipase deficiency Uncertain:1
Sep 20, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

- -

Type 1 diabetes mellitus 2;C2675071:High density lipoprotein cholesterol level quantitative trait locus 12;C3151466:Hyperlipidemia due to hepatic triglyceride lipase deficiency Uncertain:1
Feb 24, 2022
New York Genome Center
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Benign
-0.019
T
BayesDel_noAF
Pathogenic
0.20
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Benign
0.32
T;.;T;.
Eigen
Uncertain
0.64
Eigen_PC
Uncertain
0.53
FATHMM_MKL
Pathogenic
1.0
D
LIST_S2
Uncertain
0.96
D;D;.;D
MetaRNN
Benign
0.015
T;T;T;T
MetaSVM
Uncertain
-0.0078
T
MutationAssessor
Pathogenic
3.1
M;.;M;.
PhyloP100
7.2
PrimateAI
Uncertain
0.53
T
PROVEAN
Benign
-2.1
N;N;N;N
REVEL
Uncertain
0.45
Sift
Benign
0.043
D;T;D;T
Sift4G
Benign
0.16
T;T;T;T
Polyphen
1.0
D;.;D;D
Vest4
0.76
MVP
0.85
MPC
0.43
ClinPred
0.040
T
GERP RS
5.9
Varity_R
0.17
gMVP
0.68
Mutation Taster
=52/48
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs113298164; hg19: chr15-58855748; API